Find the latest clinical trials by condition, location & phase
Browse and search for drug information and related clinical trials
Explore a comprehensive list of organizations, including their profiles and details.
Latest updates on clinical trials, pharmaceuticals, and healthcare companies
Stay informed with timely notifications on clinical trials and research advancements.
No overview information available.
No background information available.
No indication information available.
No associated conditions information available.
Janux Therapeutics has initiated Phase 1b expansion studies of JANX007 in taxane-naïve metastatic castration-resistant prostate cancer patients, marking progression to earlier treatment lines.
Morgan Stanley highlights Janux Therapeutics' positive Phase 1a data for JANX007 in metastatic castration-resistant prostate cancer.
Janux Therapeutics' JANX007 demonstrated significant PSA reduction in heavily pre-treated metastatic castration-resistant prostate cancer patients.
Janux Therapeutics' JANX007 demonstrated substantial clinical activity in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients.